Tredaptive Recommended For EU Approval For The Treatment Of Mixed Dyslipidaemia And Primary Hypercholesterolaemia
May 15th 2008Drug InformationCholesterol
Merck Sharp & Dohme Limited (MSD) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended marketing approval for ‘Tredaptive’? (nicotinic acid/laropiprant, MSD) 1000 mg / 20 mg modified-release tablets for the treatment of mixed dyslipidaemia and primary hypercholesterolaemia.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
